• Login
• Home
• About
• Current
• Archives
• Search
• Submissions
• Board
• SEEd

Home > Archives > Vol 5, No 5S (2011)

Table of Contents

Editorial

Resistance and/or intolerance: one more chance! Luigia Luciano

PDF 3-6

Case report

Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib Sabina Russo, Giuseppa Penna, Arianna D’Angelo, Alessandro Allegra, Andrea Alonci, Caterina Musolino

PDF 7-14

Efficacy of nilotinib in a patient in non-optimal response after imatinib treatment but in reduced compliance to the new drug Francesca Sassolini

PDF 15-19

Complete Molecular Response due to nilotinib as III line treatment in a patient with CML and F317L point mutation of the Bcr-Abl kinase domain Maria Iovine, Giuseppe Monaco, Mario Troiano, Antonio Abbadessa

PDF 21-25

Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib Emilio Usala

PDF 27-30